The Asia-Pacific Dengue Prevention Board organized a meeting (Kuala Lumpur, Malaysia, 1–2 June 2016) to highlight points for consideration about CYD-TDV vaccine introduction and to define the most useful tools and approaches for dengue endemic countries to develop policies.
We invite you to read the full report on the "Development of Dengue Vaccines: Issues relating to dengue vaccine introduction in light of the WHO SAGE recommendations" here.
Dengue vaccines have been under development since the 1940s, but due to the limited appreciation of global dengue disease burden and of the potential markets for dengue vaccines, the industry’s interest languished throughout much of the 20th century.
In recent years, however, the development of dengue vaccines has accelerated dramatically. The first dengue vaccine to ever be registered for use in a country is Sanofi Pasteur's Dengvaxia (or CYD-TDV), first approved by Mexico in December, 2015 and later by the Philippines, Brazil, El Salvador and Costa Rica for use in individuals 9-45 years of age living in endemic areas. The Philippines has already started implementing a dengue vaccination program using Dengvaxia. Several other vaccines are in various stages of advanced development, with clinical trials currently underway on eight candidates.
Any vaccine developed must be incorporated in to the tactics already in use. Dengue vaccines will complement, but not replace, prevention methods, such as vector control, already in place. According to the WHO, drawing on the experiences of other vaccine-preventable vector-borne diseases, effective surveillance, prevention and outbreak response tools (vector control and vaccines) must continue to complement each other in reducing the burden of the disease.